Tenax Therapeutics to Participate in the Leerink Partners 2025 Global Healthcare Conference
Tenax Therapeutics (Nasdaq: TENX) has announced its participation in the upcoming Leerink Partners 2025 Global Healthcare Conference in Miami, FL. The company, which specializes in developing treatments for cardiovascular and pulmonary diseases with high unmet medical need, will be featured in a fireside chat presentation.
The presentation is scheduled for March 10, 2025, at 3:40pm ET and will include participation from Chris Giordano, President & Chief Executive Officer, and Dr. Stuart Rich, Chief Medical Officer. The Phase 3 development-stage pharmaceutical company will make both live and archived versions of the presentation available through their investor relations webpage.
Tenax Therapeutics (Nasdaq: TENX) ha annunciato la sua partecipazione alla prossima Conferenza Globale sulla Salute di Leerink Partners 2025 a Miami, FL. L'azienda, specializzata nello sviluppo di trattamenti per malattie cardiovascolari e polmonari con un elevato bisogno medico non soddisfatto, sarà presente con una presentazione in formato fireside chat.
La presentazione è programmata per il 10 marzo 2025, alle 15:40 ET e vedrà la partecipazione di Chris Giordano, Presidente e Amministratore Delegato, e Dr. Stuart Rich, Direttore Medico. La società farmaceutica in fase di sviluppo di Fase 3 renderà disponibili sia versioni live che archiviate della presentazione attraverso la loro pagina web per le relazioni con gli investitori.
Tenax Therapeutics (Nasdaq: TENX) ha anunciado su participación en la próxima Conferencia Global de Salud de Leerink Partners 2025 en Miami, FL. La compañía, que se especializa en el desarrollo de tratamientos para enfermedades cardiovasculares y pulmonares con una alta necesidad médica no satisfecha, será presentada en una charla tipo fireside.
La presentación está programada para el 10 de marzo de 2025, a las 3:40 p.m. ET e incluirá la participación de Chris Giordano, Presidente y Director Ejecutivo, y Dr. Stuart Rich, Director Médico. La compañía farmacéutica en etapa de desarrollo de Fase 3 hará disponibles versiones en vivo y archivadas de la presentación a través de su página web de relaciones con inversores.
테낙스 테라퓨틱스 (Nasdaq: TENX)는 플로리다주 마이애미에서 열리는 리어링크 파트너스 2025 글로벌 헬스케어 컨퍼런스에 참여한다고 발표했습니다. 심혈관 및 호흡기 질환의 치료제를 개발하는 전문 회사인 이 회사는 파이어사이드 챗 형식의 발표를 진행할 예정입니다.
발표는 2025년 3월 10일 오후 3시 40분 ET로 예정되어 있으며, 크리스 조르다노 사장 겸 CEO와 스튜어트 리치 박사 최고 의료 책임자가 참여합니다. 3상 개발 단계의 제약 회사는 발표의 라이브 및 아카이브 버전을 투자자 관계 웹페이지를 통해 제공할 것입니다.
Tenax Therapeutics (Nasdaq: TENX) a annoncé sa participation à la prochaine Conférence Mondiale sur la Santé de Leerink Partners 2025 à Miami, FL. L'entreprise, qui se spécialise dans le développement de traitements pour les maladies cardiovasculaires et pulmonaires avec un besoin médical non satisfait élevé, sera présentée lors d'une discussion informelle.
La présentation est prévue pour le 10 mars 2025 à 15h40 ET et comprendra la participation de Chris Giordano, Président et Directeur Général, et de Dr. Stuart Rich, Directeur Médical. L'entreprise pharmaceutique en phase de développement de Phase 3 mettra à disposition des versions en direct et archivées de la présentation sur sa page web dédiée aux relations avec les investisseurs.
Tenax Therapeutics (Nasdaq: TENX) hat seine Teilnahme an der bevorstehenden Leerink Partners 2025 Global Healthcare Conference in Miami, FL, bekannt gegeben. Das Unternehmen, das sich auf die Entwicklung von Behandlungen für kardiovaskuläre und pulmonale Erkrankungen mit hohem ungedecktem medizinischen Bedarf spezialisiert hat, wird in einer Fireside-Chat-Präsentation vorgestellt.
Die Präsentation ist für den 10. März 2025 um 15:40 Uhr ET angesetzt und wird die Teilnahme von Chris Giordano, Präsident und CEO, sowie Dr. Stuart Rich, Chief Medical Officer, umfassen. Das Pharmaunternehmen in der Phase-3-Entwicklung wird sowohl Live- als auch archivierte Versionen der Präsentation über seine Investor-Relations-Webseite zur Verfügung stellen.
- None.
- None.
CHAPEL HILL, N.C., March 03, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, today announced that the Company will participate in a fireside chat at the Leerink Partners 2025 Global Healthcare Conference, which is taking place from March 10-12, 2025, in Miami, FL.
Details of presentation:
Format: Fireside Chat
Participants: Chris Giordano, President & Chief Executive Officer, Stuart Rich, MD, Chief Medical Officer
Date and Time: March 10, 2025, at 3:40pm ET
The live and archived webcast of the presentation will be accessible from the Company’s investor relations webpage.
About Tenax Therapeutics
Tenax Therapeutics, Inc. is a Phase 3, development-stage pharmaceutical company focused on developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need. The Company owns global rights to develop and commercialize levosimendan, which it has prioritized in the near term. Tenax Therapeutics also may resume developing its unique oral formulation of imatinib. For more information, visit www.tenaxthera.com. Tenax Therapeutics’ common stock is listed on The Nasdaq Stock Market LLC under the symbol “TENX”.
Contact:
Investor and Media:
Merrill Barrett
Argot Partners
tenax@argotpartners.com
FAQ
When is Tenax Therapeutics (TENX) presenting at the Leerink Partners 2025 Conference?
Who will represent TENX at the Leerink Partners 2025 Healthcare Conference?
What type of presentation will TENX deliver at the Leerink Partners Conference?
How can investors access TENX's Leerink Partners Conference presentation?
What is the current development stage of Tenax Therapeutics (TENX)?
